Christoph Stellbrink
Christoph Stellbrink has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Ole Alexander Breithardt
Department of Electrophysiology, University of Leipzig, Heart Center, Leipzig, Germany
5 shared publications P Hanrath
4 shared publications- A.-M. Sinha
Universit tsklinikum Aachen, Dept. of Cardiology, Aachen, Germany
3 shared publications G. Beer
3 shared publicationsH. Kuhn
3 shared publicationsB Diem
2 shared publications
Latest Publications
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1)
Outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a European multicentre and multinational study
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1)
Outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a European multicentre and multinational study
- Open Access
- 1 December 2007
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 9 (suppl_I) , I113-I115
The follow-up of cardiac devices: what to expect for the future?
The number of implanted cardiac devices has dramatically increased in recent years. Moreover, these devices have developed from simple, fixed-rate pacemakers to multi-programmable systems with an ever-increasing amount of information retrievable and programming options available. With the advent of the implantable cardioverter-defibrillators and cardiac resynchronization therapy, devices have become even more complex. New sensors for heart failure monitoring may be expected to make an important impact and at the same time make follow-ups more time consuming. This will increase the demands on follow-up centres, physicians, technologists, and nurses while there is only a limited workforce available due to budgetary restrictions. Therefore, new ways of patient management after cardiac device implantation are needed. This article discusses what new approaches for patient follow-up are currently being developed and investigated in the clinical arena with an emphasis on telemetric device surveillance.
- 1 December 2007
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 9 (suppl_I) , I113-I115
Open AccessThe follow-up of cardiac devices: what to expect for the future?
The number of implanted cardiac devices has dramatically increased in recent years. Moreover, these devices have developed from simple, fixed-rate pacemakers to multi-programmable systems with an ever-increasing amount of information retrievable and programming options available. With the advent of the implantable cardioverter-defibrillators and cardiac resynchronization therapy, devices have become even more complex. New sensors for heart failure monitoring may be expected to make an important impact and at the same time make follow-ups more time consuming. This will increase the demands on follow-up centres, physicians, technologists, and nurses while there is only a limited workforce available due to budgetary restrictions. Therefore, new ways of patient management after cardiac device implantation are needed. This article discusses what new approaches for patient follow-up are currently being developed and investigated in the clinical arena with an emphasis on telemetric device surveillance.
- Open Access
- 5 May 2007
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 28 (13) , 1541-1542
It's the metabolism, stupid! Why electrophysiologists should be interested in biomarkers of heart failure
- 5 May 2007
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 28 (13) , 1541-1542
Open AccessIt's the metabolism, stupid! Why electrophysiologists should be interested in biomarkers of heart failure
- 1 December 2006
- Published by Springer Nature in Herzschrittmachertherapie + Elektrophysiologie
- Vol. 17 (4) , 205-210
Long and short QT syndrome
In the past decade molecular genetic analysis has greatly expanded our knowledge about inherited arrhythmogenic syndromes. The congenital long QT syndrome (LQTS) and the recently described short QT syndrome (SQTS), with the defining characteristic of abnormal prolongation or shortening of the QTc interval on the surface electrocardiogram, are caused by cardiac ion channel dysfunctions. These "channelopathies" show a high degree of genetic heterogeneity of the molecular pathways in terms of the relationships between genetic defects and phenotypic expression. In this brief review we summarize the current understanding of the molecular basis of long and short QT syndrome with focus on the impact of molecular genetics on the clinical management of these diseases.
- 1 December 2006
- Published by Springer Nature in Herzschrittmachertherapie + Elektrophysiologie
- Vol. 17 (4) , 205-210
Long and short QT syndrome
In the past decade molecular genetic analysis has greatly expanded our knowledge about inherited arrhythmogenic syndromes. The congenital long QT syndrome (LQTS) and the recently described short QT syndrome (SQTS), with the defining characteristic of abnormal prolongation or shortening of the QTc interval on the surface electrocardiogram, are caused by cardiac ion channel dysfunctions. These "channelopathies" show a high degree of genetic heterogeneity of the molecular pathways in terms of the relationships between genetic defects and phenotypic expression. In this brief review we summarize the current understanding of the molecular basis of long and short QT syndrome with focus on the impact of molecular genetics on the clinical management of these diseases.
- Open Access
- 10 February 2006
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 8 (3) , 161-167
First multi-centre evaluation of a knowledge-based implant-assistant for implantable cardioverter-defibrillators
Aims Modern implantable cardioverter-defibrillators (ICDs) place increasing demands on the physician, as their complexity requires more and more knowledge and effort in handling them. To overcome this problem an implant-assistant has been developed, which transfers clinical data entered by the physician into a complete set of parameters for programming a dual-chamber ICD (Tachos-DR, Biotronik, Berlin, Germany) at DFT testing (DFT-Prog) and first permanent programming (Perm-Prog) after implant. Methods and results Routine ICD implantations were initially evaluated by clinical experts at 19 centres in USA and Europe from 178 patient files. The rating of parameters was related to the number of parameters available in each patient. For DFT-Prog, 98.4% of parameter suggestions were identical to experts' expectations, an additional 1.0% were accepted, 0.5% were rejected, and none was considered harmful. This resulted in an overall acceptance of 94.4% of the DFT-Prog. For Perm-Prog, 96.1% of parameters were identical to those advised by experts, an additional 2.4% were accepted, 1.5% rejected, and seven parameters (0.04%) were considered potentially harmful by experts with an overall acceptance of 86.5%. Adaptation of the implant-assistant increased the overall acceptance to 100% for DFT-Prog and 90.6% for first Perm-Prog without any potentially harmful suggestions. Conclusion The ICD implant-assistant, which allows the physician to programme ICDs directly from clinical data, is a promising method to simplify the programming of modern ICDs.
- 10 February 2006
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 8 (3) , 161-167
Open AccessFirst multi-centre evaluation of a knowledge-based implant-assistant for implantable cardioverter-defibrillators
Aims Modern implantable cardioverter-defibrillators (ICDs) place increasing demands on the physician, as their complexity requires more and more knowledge and effort in handling them. To overcome this problem an implant-assistant has been developed, which transfers clinical data entered by the physician into a complete set of parameters for programming a dual-chamber ICD (Tachos-DR, Biotronik, Berlin, Germany) at DFT testing (DFT-Prog) and first permanent programming (Perm-Prog) after implant. Methods and results Routine ICD implantations were initially evaluated by clinical experts at 19 centres in USA and Europe from 178 patient files. The rating of parameters was related to the number of parameters available in each patient. For DFT-Prog, 98.4% of parameter suggestions were identical to experts' expectations, an additional 1.0% were accepted, 0.5% were rejected, and none was considered harmful. This resulted in an overall acceptance of 94.4% of the DFT-Prog. For Perm-Prog, 96.1% of parameters were identical to those advised by experts, an additional 2.4% were accepted, 1.5% rejected, and seven parameters (0.04%) were considered potentially harmful by experts with an overall acceptance of 86.5%. Adaptation of the implant-assistant increased the overall acceptance to 100% for DFT-Prog and 90.6% for first Perm-Prog without any potentially harmful suggestions. Conclusion The ICD implant-assistant, which allows the physician to programme ICDs directly from clinical data, is a promising method to simplify the programming of modern ICDs.
- 9 November 2005
- Published by Springer Nature in Sleep and Breathing
- Vol. 9 (4) , 159-166
Effect of cardiac resynchronization therapy on sleep quality, quality of life, and symptomatic depression in patients with chronic heart failure and Cheyne-Stokes respiration
Patients with heart failure (HF) often suffer from sleep-related breathing disorders (SRBD) like Cheyne-Stokes respiration (CSR). Cardiac resynchronization therapy (CRT) improves myocardial function and exercise capacity in patients with HF and conduction disturbances. As CRT has been shown to reduce CSR in patients with HF, it is not clear whether CRT improves quality of life and symptomatic depression by improvement of apnea/hypopnea index (AHI) and sleep quality. Forty-two HF patients with conduction disturbance before CRT were screened for CSR and evaluated for sleep quality [Pittsburgh Sleep Quality Index (PSQI)], quality of life score [36-item short form (SF-36)], depression, and exercise capacity (VO2peak) and ejection fraction (EF). Eighteen patients (three females, age 61±10, body mass index 24±4 kg m−2, EF 24±4%, QRS complex duration 156±32 ms) presented CSR with an AHI of 18±8 (11 CSR, 7 mixed). Fourteen patients showed no SRBD (PSQIpp=0.0007), with reduction of depression score (12±3 to 4.8±3, p=0.004). In patients with HF, CSR is associated with symptomatic depressive syndromes and impaired quality of life. CRT reduced CSR with improvement of sleep quality and symptomatic depression.
- 9 November 2005
- Published by Springer Nature in Sleep and Breathing
- Vol. 9 (4) , 159-166
Effect of cardiac resynchronization therapy on sleep quality, quality of life, and symptomatic depression in patients with chronic heart failure and Cheyne-Stokes respiration
Patients with heart failure (HF) often suffer from sleep-related breathing disorders (SRBD) like Cheyne-Stokes respiration (CSR). Cardiac resynchronization therapy (CRT) improves myocardial function and exercise capacity in patients with HF and conduction disturbances. As CRT has been shown to reduce CSR in patients with HF, it is not clear whether CRT improves quality of life and symptomatic depression by improvement of apnea/hypopnea index (AHI) and sleep quality. Forty-two HF patients with conduction disturbance before CRT were screened for CSR and evaluated for sleep quality [Pittsburgh Sleep Quality Index (PSQI)], quality of life score [36-item short form (SF-36)], depression, and exercise capacity (VO2peak) and ejection fraction (EF). Eighteen patients (three females, age 61±10, body mass index 24±4 kg m−2, EF 24±4%, QRS complex duration 156±32 ms) presented CSR with an AHI of 18±8 (11 CSR, 7 mixed). Fourteen patients showed no SRBD (PSQIpp=0.0007), with reduction of depression score (12±3 to 4.8±3, p=0.004). In patients with HF, CSR is associated with symptomatic depressive syndromes and impaired quality of life. CRT reduced CSR with improvement of sleep quality and symptomatic depression.
- 1 October 2005
- Published by Springer Nature in Herz
- Vol. 30 (7) , 596-600
Kardiale Resynchronisationstherapie—immer mit ICD?
Sudden cardiac death is responsible for about 50% of all deaths in heart failure. In studies on primary and secondary prevention of sudden cardiac death, the implantable cardioverter defibrillator (ICD) has proven superior to antiarrhythmic drug therapy mainly in patients with coronary artery disease and reduced left ventricular function. Thus, in recent years the question arose whether prophylactic ICD treatment can reduce mortality as well in an unselected patient group with heart failure of any etiology. This is even more important for patients that are candidates for cardiac resynchronization therapy because, first, presence of an intraventricular conduction delay indicates an increased risk of sudden death and, second, the additional operative morbidity of ICD implantation is minimal compared to implant of a biventricular pacemaker. Recent studies have proven the benefit of conventional ICD treatment in patients with heart failure as well as the benefit of biventricular pacing in heart failure patients with ventricular conduction delay. In the present article, these studies and their influence on the system choice in cardiac resynchronization therapy are discussed.
- 1 October 2005
- Published by Springer Nature in Herz
- Vol. 30 (7) , 596-600
Kardiale Resynchronisationstherapie—immer mit ICD?
Sudden cardiac death is responsible for about 50% of all deaths in heart failure. In studies on primary and secondary prevention of sudden cardiac death, the implantable cardioverter defibrillator (ICD) has proven superior to antiarrhythmic drug therapy mainly in patients with coronary artery disease and reduced left ventricular function. Thus, in recent years the question arose whether prophylactic ICD treatment can reduce mortality as well in an unselected patient group with heart failure of any etiology. This is even more important for patients that are candidates for cardiac resynchronization therapy because, first, presence of an intraventricular conduction delay indicates an increased risk of sudden death and, second, the additional operative morbidity of ICD implantation is minimal compared to implant of a biventricular pacemaker. Recent studies have proven the benefit of conventional ICD treatment in patients with heart failure as well as the benefit of biventricular pacing in heart failure patients with ventricular conduction delay. In the present article, these studies and their influence on the system choice in cardiac resynchronization therapy are discussed.